PQ6A Stock Overview

A biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. More details

PQ6A fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Does not have meaningful revenue (A$4M)

Does not have a meaningful market cap (€39M)

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Starpharma Holdings Limited Competitors

SynBiotic

DUSE:SBX

€20.5m

Biofrontera

XTRA:B8FK

€14.8m

Cantourage Group

XTRA:HIGH

€61.1m

TFF Pharmaceuticals

MUN:0K30

€9.7m

Price History & Performance

Summary of share price highs, lows and changes for Starpharma Holdings
Historical stock prices
Current Share Price	AU$0.46
52 Week High	AU$0.72
52 Week Low	AU$0.40
Beta	0.46
1 Month Change	2.22%
3 Month Change	-20.69%
1 Year Change	-36.11%
3 Year Change	-90.46%
5 Year Change	n/a
Change since IPO	-93.94%

Recent updates

Shareholder Returns

	PQ6A	DE Pharmaceuticals	DE Market
7D	2.2%	3.3%	3.4%
1Y	-36.1%	-15.5%	15.0%

Return vs Industry: PQ6A underperformed the German Pharmaceuticals industry which returned -15.5% over the past year.

Return vs Market: PQ6A underperformed the German Market which returned 15% over the past year.

Price Volatility

Is PQ6A's price volatile compared to industry and market?
PQ6A volatility
PQ6A Average Weekly Movement	8.3%
Pharmaceuticals Industry Average Movement	5.0%
Market Average Movement	6.3%
10% most volatile stocks in DE Market	12.9%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: PQ6A has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: PQ6A's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1997	40	Cheryl Maley	starpharma.com

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It is also involved in the development of dendrimer enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial.

Starpharma Holdings Limited Fundamentals Summary

How do Starpharma Holdings's earnings and revenue compare to its market cap?
PQ6A fundamental statistics
Market cap	€22.46m
Earnings (TTM)	-€7.15m
Revenue (TTM)	€2.38m

9.5x

P/S Ratio

-3.1x

P/E Ratio

Is PQ6A overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PQ6A income statement (TTM)
Revenue	AU$4.16m
Cost of Revenue	AU$9.91m
Gross Profit	-AU$5.75m
Other Expenses	AU$6.78m
Earnings	-AU$12.52m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.03
Gross Margin	-138.24%
Net Profit Margin	-301.18%
Debt/Equity Ratio	0.5%

How did PQ6A perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/06 01:46
End of Day Share Price	2025/05/06 00:00
Earnings	2024/12/31
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Starpharma Holdings Limited is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Dennis Hulme	APP Securities Pty Ltd.
Tanushree Jain	Bell Potter
Matthijs Smith	Canaccord Genuity